Financials data is unavailable for this security.
View more
Year on year Novo Nordisk A/S grew revenues 25.03% from 232.26bn to 290.40bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 20.68% net income growth from 83.68bn to 100.99bn.
| Gross margin | 84.33% |
|---|---|
| Net profit margin | 34.51% |
| Operating margin | 44.63% |
| Return on assets | 26.55% |
|---|---|
| Return on equity | 88.12% |
| Return on investment | 54.15% |
More ▼
Cash flow in DKKView more
In 2024, Novo Nordisk A/S increased its cash reserves by 8.78%, or 1.26bn. The company earned 120.97bn from its operations for a Cash Flow Margin of 41.66%. In addition the company generated 8.74bn cash from financing while 128.90bn was spent on investing.
| Cash flow per share | 26.69 |
|---|---|
| Price/Cash flow per share | 12.51 |
| Book value per share | 31.21 |
|---|---|
| Tangible book value per share | 6.57 |
More ▼
Balance sheet in DKKView more
| Current ratio | 0.7386 |
|---|---|
| Quick ratio | 0.5571 |
| Total debt/total equity | 0.857 |
|---|---|
| Total debt/total capital | 0.4615 |
More ▼
Growth rates in DKK
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 21.28% and 21.54%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
| Div yield(5 year avg) | 1.55% |
|---|---|
| Div growth rate (5 year) | 22.25% |
| Payout ratio (TTM) | 48.45% |
| EPS growth(5 years) | 22.55 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 17.92 |
More ▼
